STAT3 and cancer: Furthermore, recent studies have reported that (i) STAT3 inhibition can potentiate the antitumor activity of cisplatin [16]; (ii) inhibitor of Janus kinase 2 (JAK2) blocks STAT3 activation and, thus, overcome tamoxifen resistance [17]; and (iii) activation of STAT3 induces resistance to many targeted cancer therapies [18].